Hypocholesterolemia and cancer: Tumor cells induce enhanced LDL uptake by non-tumor cells and stimulate oxidative modification of LDL

Pathophysiology

Volumn 6, Issue 3, 1999, Pages 205-210

  Fuhrman, Bianca ^a   Wolfovitz, Efrat ^a   Cogan, Uri ^a   Brook, Gerald J ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Hypocholesterolemia; Low density lipoprotein; Tumor cells

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; DISSEMINATED CANCER; HUMAN; HUMAN CELL; HYPOCHOLESTEROLEMIA; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PLASMA CLEARANCE; PRIORITY JOURNAL; TUMOR CELL;

EID: 0032760708     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4680(99)00023-1     Document Type: Article

References (43)

1. Ginsberg H., Gilbert H.S. Hypocholesterolemia in myeloproliferative disease with myelofibrosis. Prog. Clin. Biol. Res. 154:1984;345-357.
2. Reverter J.C., Sierra J., Marti-Tutusaus J.M., Monteserrat E., Granena A., Rozrnan C. Hypocholesterolemia in acute myelogenous leukemia. Eur. J. Haematol. 41:1988;317-320.
3. Markel A., Brook G.J. Cancer and hypocholesterolemia. Isr. J. Med. Sci. 30:1994;787-793.
4. Marini A., Carulli G., Azara A., Grassi B., Ambrogi F. Serum cholesterol and triglycerides in hematological malignancies. Acta Haematol. 81:1989;75-79.
5. Cooper R.A., Strauss S.F. Shinitzky M. Physiology of Membrane Fluidity. 1:1984;73-97 CRC Press, Boca Raton, FL.
6. Ho Y.K., Smith R.G., Brown M.S., Goldstein J.L. Low density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood. 52:1978;1099-1114.
7. Clayman R.V., Bilhartz L.E., Spady D.K., Buja L.M., Dietschy J.M. Low density lipoprotein-receptor activity is lost in vivo in malignantly transformed renal tissue. FEBS Lett. 196:1986;87-90.
8. Fabricant M., Broitman S.A. Evidence for deficiency of low density lipoprotein receptor on human colonic carcinoma cell lines. Cancer Res. 50:1990;632-636.
9. Ginsberg H., Gilbert H.S., Gibson J.C., Le N.A., Brown W.V. Increased low density lipoprotein catabolism in myeloproliferative disorders. Am. Intern. Med. 96:1982;311-316.
10. Vitols S., Gahrton G., Ost A., Peterson C. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood. 63:1984;1186-1193.
11. Gueddari N., Favre G., Hachem H., Marek E., Le Gaillard F., Soula G. Evidence for up-regulated low density lipoprotein receptor in human lung adenocarcinoma cell line A549. Biochimie. 75:1993;811-819.
12. Vitols S., Angelin B., Ericsson S., Gahrton G., Juliusson G., Masquelier M., Paul C., Peterson C., Rudling M., Soderberg-Reid K. et al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc. Natl. Acad. Sci. USA. 87:1990;2598-2602.
13. Cerutti P.A. Oxidant stress and carcinogenesis. Eur. J. Clin. Invest. 21:1991;1-5.
14. Halliwell B. Oxidants and human disease: some new concepts. FASEB J. 1:1987;358-364.
15. Lavy A., Brook G.J., Dankner G., Ben Amotz A., Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism. 40:1991;794-799.
16. Keidar S., Kaplan M., Shapira H., Brook G.J., Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis. 104:1994;71-84.
17. Mshigaki I., Hagihara M., Tsunekawa H., Maseki M., Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem. Med. 25:1981;373-378.
18. Gey K.F. Prospects for the prevention of free radical disease, regarding cancer and cardiovascular disease. Brit. Med. Bull. 49:1993;679-699.
19. Fuhrman B., Oiknine J., Keidar S., Ben-Yaish L., Kaplan M., Aviram M. Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL. Free Radic. Biol. Med. 23:1997;34-46.
20. Fuhrman B., Oiknine J., Aviram M. Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL, and affects their secretory properties. Atherosclerosis. 111:1994;65-78.
21. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:1989;915-924.
22. Parthasarathy S., Printz D.J., Boyd L., Joy L., Steinberg D. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis. 6:1986;505-510.
23. Teicher B.A., Holden S.A., Herman T.S., Sotomayor E.A., Khandekar V., Rosbe K.W., Brann T.W., Korbut T.T., Frei E. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int. J. Cancer. 47:1991;252-260.
24. Eliyahu D., Raz A., Gruss P., Givol D., Oren M. Participation of p53 cellular tumor antigen in transformation of normal embryonic cells. Nature. 312:1984;646-649.
25. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem. Med. 30:1983;111-118.
26. Eisenberg S., Bilheimer D.W., Levy R.I., Lindgren F.T. On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein. Biochem. Biophys. Acta. 326:1973;361-377.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
28. Bierman E.L., Stein O., Stein Y. Lipoprotein uptake and metabolism by rat aortic smooth muscle cells in tissue culture. Circ. Res. 35:1974;136-150.
29. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol. 52:1978;302-310.
30. Shinitzky M. Membrane fluidity in malignancy. Adversative and recuperative. Biochim. Biophys. Acta. 738:1984;251-261.
31. Shinitzky M. Isr. J. Chem. 12:1974;879-891.
32. Stopeck A.T., Nicholson A.C., Mancini F.P., Haiiar D.P. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. J. Biol. Chem. 268:1993;17 489-17 494.
33. Ueyama Y., Matsuzawa Y., Yamashita S., Funahashi T., Sakai N., Nakamura T., Kubo M., Tarui S. Hypocholesterolemic factor from gallbladder cancer cells. Lancet. 336:1990;707-709.
34. Grove R.I., Mazzucco C.E., Radka S.F., Shoyab M., Kiener P.A. Oncostatin M up-regulates low density lipoprotein receptors in HepG2 cells by a novel mechanism. J. Biol. Chem. 266:1991;18 194-18 199.
35. Evans R.D., Argiles J.M., Williamson D.H. Metabolic effects of tumor necrosis factor-alpha (cachectin) and interleukin-1. Clin. Sci. 77:1989;357-364.
36. Grunfeld C., Feingold K.R. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy. 3:1991;143-158.
37. Greenberg E.R., Sporn M.B. Antioxidant vitamins, cancer, and cardiovascular disease. N. Engl. J. Med. 334:1996;1189-1190.
38. National Research Council, Committee on diet and health, food and nutrition board, commission on life science, diet and health: implications for reducing chronic disease risk, National Academy Press, Washington DC, 1989.
39. Byers T., Perry G. Dietary carotenes, vitamin C, and vitamin E as protective antioxidants in human cancers. Ann. Rev. Nutr. 12:1992;139-159.
40. Loft S., Poulsen H.E. Cancer risk and oxidative DNA damage in man. J. Mol. Med. 74:1996;297-312.
41. Toyokuni S., Okamoto K., Yodoi J., Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 358:1995;1-3.
42. della Rovere F., Broccio M., Granata A., Zirilli A., Brugnano L., Artemisia A., Broccio G. Anti free radical action of calcium antagonists and H1 and H2 receptors antagonists in neoplastic disease. Anticancer Res. 16:1996;1749-1754.
43. Aviram M., Dankner G., Cogan U., Hochgraf E., Brook J.G. Lovastatin inhibits low density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism. 41:1992;229-235.